⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Imeglimin
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-18 — Imeglimin provides dual hepatic and skeletal muscle protection in experimental MASH-associated sarcopenia.: Mouse MASH-associated sarcopenia model (imeglimin 200 mg/kg BID × 6 wk) plus IL-6-injured C2C12 myotubes: preserved muscle mass and grip strength, reduced hepatic injury, restored mitochondrial function, AKT–mTOR signaling, NAD+/NAMPT, and autophagy — with no change in fasting glucose or insulin. [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
Imeglimin provides dual hepatic and skeletal muscle protection in experimental MASH-associated sarcopenia.
18-sep-2026
novelty 3
per-area 3
strengthens